Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Gout: HELP
Articles by Sue Jowett
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Sue Jowett wrote the following article about Gout.
 
+ Citations + Abstracts
1 Article Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. 2020

Roddy, Edward / Clarkson, Kris / Blagojevic-Bucknall, Milica / Mehta, Rajnikant / Oppong, Raymond / Avery, Anthony / Hay, Elaine M / Heneghan, Carl / Hartshorne, Liz / Hooper, Julie / Hughes, Gemma / Jowett, Sue / Lewis, Martyn / Little, Paul / McCartney, Karen / Mahtani, Kamal R / Nunan, David / Santer, Miriam / Williams, Sam / Mallen, Christian D. ·Primary Care Centre Versus Arthritis; School of Primary, Community and Social Care, Keele University, Keele, UK e.roddy@keele.ac.uk. · Haywood Academic Rheumatology Centre, Midland Partnership NHS Foundation Trust, Stoke-on-Trent, UK. · Primary Care Centre Versus Arthritis; School of Primary, Community and Social Care, Keele University, Keele, UK. · Keele Clinical Trials Unit, Keele University, Keele, UK. · Birmingham Acute Care Research/Heart of England NHS Foundation Trust/Institute of Applied Health Research (BCTU), University of Birmingham, Birmingham, UK. · Health Economics, University of Birmingham, Birmingham, UK. · Division of Primary Care, University of Nottingham, Nottingham, UK. · Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. · Primary Care and Population Sciences, University of Southampton, Southampton, UK. ·Ann Rheum Dis · Pubmed #31666237.

ABSTRACT: OBJECTIVES: To compare the effectiveness and safety of naproxen and low-dose colchicine for treating gout flares in primary care. METHODS: This was a multicentre open-label randomised trial. Adults with a gout flare recruited from 100 general practices were randomised equally to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three times per day for 4 days. The primary outcome was change in worst pain intensity in the last 24 hours (0-10 Numeric Rating Scale) from baseline measured daily over the first 7 days: mean change from baseline was compared between groups over days 1-7 by intention to treat. RESULTS: Between 29 January 2014 and 31 December 2015, we recruited 399 participants (naproxen n=200, colchicine n=199), of whom 349 (87.5%) completed primary outcome data at day 7. There was no significant between-group difference in average pain-change scores over days 1-7 (colchicine vs naproxen: mean difference -0.18; 95% CI -0.53 to 0.17; p=0.32). During days 1-7, diarrhoea (45.9% vs 20.0%; OR 3.31; 2.01 to 5.44) and headache (20.5% vs 10.7%; 1.92; 1.03 to 3.55) were more common in the colchicine group than the naproxen group but constipation was less common (4.8% vs 19.3%; 0.24; 0.11 to 0.54). CONCLUSION: We found no difference in pain intensity over 7 days between people with a gout flare randomised to either naproxen or low-dose colchicine. Naproxen caused fewer side effects supporting naproxen as first-line treatment for gout flares in primary care in the absence of contraindications. TRIAL REGISTRATION NUMBER: ISRCTN (69836939), clinicaltrials.gov (NCT01994226), EudraCT (2013-001354-95).